Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-EQPX-02-01)
Text and Data Mining valid from 2020-01-21
Received: 7 October 2019
Accepted: 3 January 2020
First Online: 21 January 2020
: O.M. and F.M. are inventors in patent describing methods to modulate immune responses to AAV and to prevent or remove anti-AAV antibodies. F.M. is employee and equity holder of Spark Therapeutics. P.M. is employee and equity holder of Ask Bio. C.M. is employee of Genosafe. O.M. is employee of Miltenyi Biotech. All other authors declare no competing interests.